Home Tags Pyrrolobenzodiazepine

Tag: pyrrolobenzodiazepine

First Clinical Data from ADCT-402 Demonstrates Encouraging Antitumor Activity in r/r...

The first clinical data from an ongoing Phase I clinical trial evaluating ADCT-402 for the treatment of relapsed or refractory non-Hodgkin’s lymphoma has been...

U.S. FDA Lifts Clinical Hold Phase I Trials of Vadastuximab Talirine

The U.S. Food and Drug Administration (FDA) confirmed today that it has lifted the clinical hold on phase 1 trials of vadastuximab talirine (SGN-CD33A;...

Novel Cancer Therapeutics Drive Therapy Market

An increased need for better cancer treatment continues to boost the global cancer biological therapy market. According to a report published by Global Market...

Phase I Trial of SGN-CD352A in Relapsed or Refractory Multiple Myeloma...

This week the first patient enrolled in a multi-center phase I clinical trial of SGN-CD352A for the treatment of patients with relapsed or refractory...

Cancer Research Technology, University of Copenhagen and ADC Therapeutics Sign Agreement

Cancer Research Technology UK and the University of Copenhagen announced their agreement with Switzerland-based ADC-Therapeutics SA  to develop novel antibody therapeutics for the treatment...

Regeneron and MedImmune Sign Licensing Agreement for Pyrrolobenzodiazepine-based Payload and Linker...

This month Regeneron Pharmaceuticals, a science-based biopharmaceutical company based in Tarrytown, New York and MedImmune, the global biologics research and development arm of AstraZeneca  entered...

First Patient Dosed in Phase I Trial of ADCT-402 in CD-19...

Late last week, Swiss based ADC Therapeutics, an oncology drug development company that specializes in the development of proprietary antibody-drug conjugates (ADCs) targeting major...

Improving the Potency and Toxicity Profile of Antibody-drug Conjugates

Currently, there are more than 30 antibody drug conjugates or ADCs in clinical trials, with many more expected in the near future. ADCs are...

First Patient Dosed in Phase I Trial of ADCT-301 Trial

Earlier this month ADC Therapeutics, a Swiss-based oncology drug development company, dosed the first patient in a Phase I trial to evaluate ADCT-301, also...

New Anticancer Drugs Show Promise in the Treatment of Solid Tumors

A number of novel anticancer drugs are showing very promising results in the treatment of solid cancers. These cancers, including various forms of lung cancers,...